Detalhe da pesquisa
1.
The Landscape of US and Global Rare Tumor Research Programs: A Systematic Review.
Oncologist
; 29(2): 106-116, 2024 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37878787
2.
Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma.
J Neurooncol
; 167(2): 339-348, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38372904
3.
Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors.
J Neurooncol
; 167(2): 349-359, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38427131
4.
Childhood cancer data initiative: Status report.
Pediatr Blood Cancer
; 71(2): e30745, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37889049
5.
Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.
Clin Trials
; 21(1): 67-72, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37269078
6.
Development and pilot validation of a novel disfigurement severity scale for plexiform neurofibromas in children with neurofibromatosis type 1.
Clin Trials
; 21(2): 189-198, 2024 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37877369
7.
Outcome of Patients With Malignant Peripheral Nerve Sheath Tumors Enrolled on Sarcoma Alliance for Research Through Collaboration (SARC) Phase II Trials.
Oncologist
; 28(5): 453-459, 2023 05 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36724001
8.
Selumetinib in Children with Inoperable Plexiform Neurofibromas.
N Engl J Med
; 382(15): 1430-1442, 2020 04 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32187457
9.
Retrospective Cohort Analysis of the Impact of Puberty on Plexiform Neurofibroma Growth in Patients with Neurofibromatosis Type 1.
J Pediatr
; 260: 113513, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37244583
10.
Longitudinal association between executive function and academic achievement in children with neurofibromatosis type 1 and plexiform neurofibromas.
J Int Neuropsychol Soc
; 29(9): 839-849, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36750981
11.
NCI intramural program approach to rare tumors: Natural history study of rare solid tumors in children and adults: A longitudinal, comprehensive data and biospecimen collection protocol.
Pediatr Blood Cancer
; : e30495, 2023 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37345354
12.
The NIH pediatric/young adult chordoma clinic and natural history study: Making advances in a very rare tumor.
Pediatr Blood Cancer
; : e30358, 2023 Jun 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37347686
13.
Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome.
Am J Hum Genet
; 104(3): 484-491, 2019 03 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30803705
14.
Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.
PLoS Med
; 18(8): e1003734, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34464388
15.
Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.
Pediatr Blood Cancer
; 68(11): e29282, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34383370
16.
Are Some Randomized Clinical Trials Impossible?
J Pediatr Orthop
; 41(1): e90-e93, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32852366
17.
A Systematic Review of Pediatric Phase I Trials in Oncology: Toxicity and Outcomes in the Era of Targeted Therapies.
Oncologist
; 25(6): 532-540, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31943534
18.
A molecular basis for neurofibroma-associated skeletal manifestations in NF1.
Genet Med
; 22(11): 1786-1793, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32601387
19.
Advancing RAS/RASopathy therapies: An NCI-sponsored intramural and extramural collaboration for the study of RASopathies.
Am J Med Genet A
; 182(4): 866-876, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31913576
20.
Predictors of cognitive development in children with neurofibromatosis type 1 and plexiform neurofibromas.
Dev Med Child Neurol
; 62(8): 977-984, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32052421